Questor targets C$10m 2027 revenue after Q2 sales fall to just C$240,000

Questor Technology Inc. (TSXV: QST) reported Q2 2026 revenue of just C$239,880, down approximately 92% from C$3.02 million a year earlier, as long international sales cycles and low utilisation of its rental fleet sharply reduced activity. Gross profit swung from positive C$1.59 million to a C$260,139 loss, adjusted EBITDA deteriorated from positive C$871,374 to negative C$535,896 and the company recorded a C$780,287 quarterly loss.

For the first six months, revenue was C$739,188 compared with C$5.38 million a year earlier, while adjusted EBITDA moved from positive C$1.35 million to negative C$358,035. Questor said commissioning of equipment delivered to Iraq had been pushed into Q3 because of Middle East conflict, while much of its rental fleet remained idle.

Despite the weak numbers, QST closed unchanged at C$0.41 on August 28 after trading between C$0.40 and C$0.41. The absence of a sell-off is notable because the stock had already climbed from C$0.27 on August 20 to C$0.41 by August 27, a gain of roughly 52%, as investors reacted to Questor’s strategic reset and proposed acquisition of Emission Rx.

How severe was Questor Technology’s Q2 revenue deterioration?

Quarterly revenue declined by approximately C$2.78 million year on year, leaving Questor with less than 8% of the revenue it generated in Q2 2025. Fixed operating costs remained while sales and rentals fell, causing the business to report a gross loss before corporate overheads were fully considered.

The weakness was not confined to one quarter. First-half revenue of C$739,188 was down about 86% from C$5.38 million, while the six-month result moved from a C$713,326 profit to an C$894,991 loss. Questor attributed the decline principally to extended international project timelines, low rental utilisation and higher legal and professional costs associated with corporate-governance disputes and litigation involving its former chief executive.

The company nevertheless remains debt-free and reported working capital of C$4.85 million at June 30, up from C$3.88 million at the end of 2025. That liquidity gives the board greater flexibility to attempt a turnaround than the income statement alone might suggest.

Why does Questor want to acquire Emission Rx after years of litigation?

Questor signed a non-binding letter of intent on August 20 to acquire privately held Emission Rx Ltd. for total consideration of up to approximately C$3 million. The structure includes C$1 million of fixed cash consideration, 3.33 million Questor shares valued at roughly C$1 million and an earn-out of up to C$1 million subject to performance criteria. Questor said no external financing would be required.

Emission Rx generated approximately C$4 million of revenue in 2025 and has an installed base exceeding 800 units across five product lines. That annual revenue alone is more than five times Questor’s entire first-half 2026 revenue, highlighting how material the target could be to the current operating scale if the transaction closes.

The transaction would also resolve about eight years of litigation through mutual releases. Questor recovered C$1.4 million of cash during 2026 from litigation and associated proceedings involving Emission Rx, but the proposed acquisition would replace continued legal confrontation with an operating combination.

There is an unusual governance condition attached. The letter of intent terminates automatically if a majority of Questor’s current directors are not re-elected at the September 9 annual meeting, where the company expects a contested board election. Closing is targeted for on or before October 1 and remains subject to due diligence, definitive agreements and TSX Venture Exchange approval.

Can Questor realistically move from C$0.7m of H1 revenue to C$10m in 2027?

Questor’s Phase III strategy targets C$10 million of revenue in 2027 and C$15 million in 2029. The company says those targets were established before the Emission Rx proposal and therefore exclude any contribution from the acquisition.

Annualising first-half 2026 revenue produces a simple run rate of roughly C$1.48 million, although that calculation does not account for project timing and should not be treated as a forecast. A C$10 million 2027 target would be nearly seven times that depressed run rate, showing how much improvement Questor expects from redeploying existing rental equipment, completing international installations and restoring equipment sales.

The company owns more than 100 rental incinerators and is prioritising putting that fleet back to work in Canada and the United States before committing substantial additional capital elsewhere. Mexico is another focus, while installations involving TotalEnergies and SLB in Libya and projects in Nigeria and Iraq provide international reference sites.

Questor is separately reviewing its 1,500-kilowatt Organic Rankine Cycle waste-heat-to-power program. An independent consultant is assessing technical readiness, remaining capital requirements, market potential and returns, with the board expected to determine whether and how the project should proceed after receiving that review.

Why did QST shares hold steady despite such a weak quarter?

The August 28 close of C$0.41 left Questor with a market capitalisation of approximately C$11.4 million and a 52-week trading range of C$0.20 to C$0.67. The shares had gained roughly 44% over the preceding month and more than 50% from the August 20 close before investors even received the Q2 numbers.

That chronology suggests the market has recently been trading the strategic reset more aggressively than trailing earnings. The proposed Emission Rx transaction, Phase III plan, board changes and prospective fleet redeployment collectively offer a route toward a very different revenue profile, while the debt-free balance sheet gives Questor some time to execute it.

The valuation also makes the proposed acquisition material. A maximum C$3 million purchase price equals roughly 26% of Questor’s August 28 market capitalisation, while Emission Rx’s reported C$4 million of 2025 revenue is substantial compared with Questor’s current sales base.

The risk is that Questor’s turnaround now depends on several moving pieces simultaneously: winning a contested shareholder vote, completing an acquisition, redeploying idle equipment, restoring international project execution and deciding whether further investment in the ORC program is justified. The unchanged post-results share price suggests investors were prepared to look through an exceptionally weak Q2, but the C$10 million 2027 revenue objective leaves little room for another year of deployment delays.